Abstract: |
Iodine-131-3F8, a murine IgG3 monoclonal antibody specific for ganglioside G(D2) was evaluated by radioimmunoscintigraphy in 42 patients with neuroblastoma. Comparison was made with I-131-metaiodobenzylguanidine (MIBG), Tc-99m-methylene diphosphonate (MDP) bone scans, as well as computed axial tomography (CT) or magnetic resonance imaging (MRI). Iodine-131-3F8 detected more abnormal sites (283) than [I-131] MIBG (138) or Tc-99m-MDP (69), especially in patients with extensive disease. In 20 patients with soft-tissue tumors demonstrated by CT/MRI, I-131-3F8 detected the disease in 18. Upon surgical resection, two tumors interpreted as negative with I-131-3F8 imaging revealed ganglioneuroma, one showing microscopic foci of neuroblastoma. In contrast, I-131-3F8 imaging identified tumors that were confirmed histologically as neuroblastomas. In 26 patients with evidence of marrow disease by antibody scans, 14/26 had confirmation by iliac crest marrow aspirate/biopsy examinations. We conclude that I-131-3F8 scintigraphy has clinical utility in the management of patients with neuroblastoma by improving the sensitivity of tumor detection. |